| TMO |
Report |
Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~3.5% vs cons 3.05% |
MEDIUM |
| TMO |
Report |
Adj. EPS Diluted (Q2 2026) |
BEAT |
pred ~$5.85 vs cons $5.76 |
MEDIUM |
| TMO |
Report |
Pharma Services Revenue (Q2 2026) |
MISS |
pred ~$1.88B vs cons $1.91B |
LOW |
| TMO |
Guide |
FY 2026 Revenue (FY 2026) |
BETTER |
guide ~$47.8B-$48.5B vs cons $47.77B |
MEDIUM |
| TMO |
Guide |
FY 2026 Adj. EPS (FY 2026) |
BETTER |
guide ~$25.00-$25.40 vs cons $24.85 |
MEDIUM |
| TMO |
Guide |
Q3 2026 Organic Growth Commentary (Q3 2026) |
BETTER |
implied ~4-4.5% vs cons ~3.2% |
LOW |
| TMO |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| TMO |
Return |
5-day cumulative residual |
+1.5% (STABILIZE) |
STABILIZE - FY guide raise drives modest estimate revisions; large run-in limits follow-through |
MEDIUM |